Navigation Links
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Date:7/2/2009

ssolved tablets and nasal snorting of crushed tablets. The Acurox(R) Tablets NDA was originally accepted for filing by FDA earlier this year with a priority review classification.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of Aversion(R) (abuse deterrent) Technology product candidates and other innovative abuse deterrent technologies. Acura and King jointly developed Acurox(R) Tablets and are developing three additional opioid analgesic product candidates utilizing Aversion(R) Technology pursuant to a 2007 License, Development and Commercialization Agreement.

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacturing and marketing of pharmaceutical products for food producing animals.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). When used in this press release, the words "estimate," "project," "anticipate," "expect," "intend," "believe," and similar expressions are intended to identify forward-looking statements. Examples of forward looking statements in this press release include statements concerning the Companies' expectations regarding the timing or content of their response to the FDA conc
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
2. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
3. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
5. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
10. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
11. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...e-FirstCall/ -- Recession in domestic and internat...d Healthcare Products in the first quarter of fisc...s declines pushed Allied into a loss for the quart...00, or negative 9 cents per share, compared to a n... cents per share. ,, Sales fell about 21 perce...
(Date:11/6/2009)...ewswire/ -- Kaiser Foundation Health Plan, Inc., K...sidiaries reported today a combined total operatin...eptember 30, 2009, compared to $10.2 billion in th...the third quarter was $336 million, compared to $3...non-operating income was $233 million in the third...
(Date:11/6/2009)...re-USNewswire/ -- America,s Specialty Medicines Co...arket and smaller innovator pharmaceutical compani..."Affordable Health Care for America Act," introduc...r companies fear that the cumulative effect of a h...fforts to bring new medicines to market. ,, F...
Breaking Medicine Technology:Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2Cancer Endangers Some Wildlife Species 50683 1Cancer Endangers Some Wildlife Species 50683 2Odd Behaviors on Ambien Linked to Brain Circuitry 50681 1Odd Behaviors on Ambien Linked to Brain Circuitry 50681 2JNCI news brief 3A Improving the biomarker pipeline for early cancer detection 50679 1
...lin Highlights Phase 2 Data Showing 31%,Partial Re...e to Perifosine, Used as a Single Agent and Phase... Toxicity When Combined with Sorafenib, NEW... announced positive phase 1 & 2 data of perifosine...arcinoma (RCC). In an oral presentation,entitled "...
...l Scare Every day brings new reports of students ... MRSA (methicillin-resistant staphylococcus aureus...t,s easily acquired in,public schools, universitie...e skin abscesses and/or infections. While MRSA is...attacks,those with low immune systems, children an...
Other Medicine Technology:Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 2Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 3Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 4Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 6Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 7An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R) 2An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R) 3
(Date:11/6/2009)... /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (N...will report financial results for the third quarte...y, November 9, 2009. Cardiome will hold a teleconf...Pacific) on that day to discuss the results. ,, To...806 or 888-789-9572 and reference conference 23452...
(Date:11/6/2009)...v. 6 Authentidate Holding Corp. (Nasdaq: ADAT ),... Exchange and workflow management services, has in...ealthcare to be easily integrated with one of the ...efinitive Homecare Solutions, CPR+(TM). Inscrybe ... Solutions Provider program, a program designed to...
(Date:11/6/2009)...& Lymphoma Society (LLS) will again be partici... in its first two campaigns this past spring and s...S,s blood cancer research funding and patient educ..., taking place from November 12th to 15th, Gap Inc... participants can use (in-store only) at all Gap I...
(Date:11/6/2009)...f America, Inc. (the "REIT"), a self-managed, non-...e execution of a Purchase and Sale Agreement (the ...located in Englewood, Colorado for approximately $...s located within the Englewood City Center, a tran...mpden Place is located near the Swedish Medical Ce...
(Date:11/6/2009)...urgent message to the U.S. House of Representative...in debate over procedures related to abortion and ...ting to discuss proposed amendments to the bill, t...permit discussion of "an amendment to keep in plac...cience protections." Some in the House seek a "clo...
Breaking Medicine News(10 mins):Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:Authentidate Introduces New Interface for Inscrybe Healthcare with Definitive Homecare Solutions' CPR+ 2Health News:Authentidate Introduces New Interface for Inscrybe Healthcare with Definitive Homecare Solutions' CPR+ 3Health News:Authentidate Introduces New Interface for Inscrybe Healthcare with Definitive Homecare Solutions' CPR+ 4Health News:Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 3Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 2Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 3Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 4Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 5
...for the treatment of mild to moderate obstructive ... disruptive snoring.// The effectiveness of palata...nd snoring has been demonstrated in a number of cl...hy data, with additional evidence of improvement i...
...taking four short walks a day to lower your blood ....// Indiana University researchers have repor...tension, a study that compared the effects of four...lly a situation in which blood pressure ranges fro...
...yngeal cancer -- a type of cancer that develops in...at assists with breathing, talking, eating, chewin...ion alone or with chemoradiation. The addition of ... other parts of the body. In the oropharynge...
... in Science X-Press, an advanced, online edition o...mmunodeficiency may cause susceptibility// to herp... to the current scientific theory of how genes fun... cells from two French children with a deficiency ...
...ion of eight hundred billion dollars by The World ...flu pandemic//, has gone in for further reckoning.... costs could be up to two trillion U.S dollars, as...t Asia and the Pacific, also leading the bank's av...
...of two genes, REG1A and EXTL3 in the patients with... according to a new study from the Max Delbrueck C...REG1A expression was also significantly higher in ... and may eventually help in making decisions about...
Other Medicine News:Health News:Palatal Implant Procedure Proven Effective in Eliminating Snoring 2Health News:Palatal Implant Procedure Proven Effective in Eliminating Snoring 3Health News:Is Radiation or Chemoradiation Best for Oropharyngeal Cancer Patients 2Health News:Is Radiation or Chemoradiation Best for Oropharyngeal Cancer Patients 3Health News:Genetic susceptibility in viral encephalitis 2Health News:REG1A and its receptor EXTL3 signal the recurrence of colorectal cancer 2
Direct Image 30 Prism
Direct Image High-Mag
...resolution, high magnification and field of view a...gn separates for easy cleaning, while maintaining ...d saline or water to the contact element, then loc...enses The ACS Vitrectomy Lenses from Volk can be s...
...e DynaView 156 is designed to attain a full field ... both premature infants and adult patients. Featur...lement, the Volk DynaView 156 revolutionizes retin...equirement for lens sparing vitrectomies in ROP. I...
Medicine Products: